#Allogeneic stem cell transplant precautions free
Three year-event free survival (EFS) and overall survival (OS) were 38% and 44%, respectively. Seventy-four percent had received a previous auto-SCT (ASCT) and the median number of lines pre-allo-SCT was 3 (range 1–9). Our objective was to analyze long term outcomes. We performed a retrospective multicenter study including 140 patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who underwent allogeneic hematopoietic stem cell transplantation (allo-SCT) from March 1995 to November 2018. on behalf of the Grupo Español de Trasplante Hematopoyético (GETH) and Grupo Español de Linfoma y Trasplante Autólogo (GELTAMO)īone Marrow Transplantation volume 56, pages 1919–1928 ( 2021) Cite this article.Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study
0 kommentar(er)
